SCHEMBL5645384

SCHEMBL5645384

Cc1cc(OC(F)(F)F)cc2c1OC(C(F)(F)F)C(C(=O)O)=C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 20/20 1.00
PTGS1 P23219 14/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5642736 1.00 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL5646952 1.00 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL6330212 0.99 PTGS2 (0.98) PTGS2PTGS1
SCHEMBL27648388 0.99 PTGS2 (0.98) PTGS2PTGS1
SCHEMBL19097654 0.92 PTGS2 (0.84) PTGS2PTGS1
SCHEMBL19097655 0.92 PTGS2 (0.84) PTGS2PTGS1
SCHEMBL16893832 0.89 PTGS2 (0.80) PTGS2PTGS1
SCHEMBL16893829 0.89 PTGS2 (0.80) PTGS2PTGS1
SCHEMBL5646380 0.89 PTGS2 (0.80) PTGS2PTGS1
SCHEMBL6330206 0.88 PTGS2 (0.78) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170196835-A1 COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT Euclises Pharmaceuticals, Inc. 2017-07-13 US claimed
US-7259266-B2 Benzopyran compounds useful for treating inflammatory conditions PHARMACIA CORPORATION (US) 2007-08-21 US claimed
CN-1768050-A Benzopyran compounds for the treatment of inflammation PHARMACIA CORP (US) 2006-05-03 CN claimed
EP-1615905-A2 BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS Pharmacia Corporation (US) 2006-01-18 EP claimed
US-20050148777-A1 Benzopyran compounds useful for treating inflammatory conditions CARTER JEFFERY (US) 2005-07-07 US claimed
WO-2004087686-A2 BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS PHARMACIA CORPORATION (US) 2004-10-14 WO claimed
EP-3094333-B1 NO-RELEASING NITROOXY-CHROMENE CONJUGATES EUCLISES PHARMACEUTICALS INC (US) 2020-10-14 EP disclosed
US-10266511-B2 No-releasing nitrooxy-chromene conjugates Euclises Pharmaceuticals, Inc. (US) 2019-04-23 US disclosed
US-20170196835-A1 COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT Euclises Pharmaceuticals, Inc. 2017-07-13 US disclosed
US-20160340330-A1 NO-RELEASING NITROOXY-CHROMENE CONJUGATES Euclises Pharmaceuticals, Inc. 2016-11-24 US disclosed
US-20150197500-A1 NO-RELEASING GUANIDINE-CHROMENE CONJUGATES EUCLISES PHARMACEUTICALS INC (US) 2015-07-16 US disclosed
US-7259266-B2 Benzopyran compounds useful for treating inflammatory conditions PHARMACIA CORPORATION (US) 2007-08-21 US disclosed
US-7259266-B2 Benzopyran compounds useful for treating inflammatory conditions PHARMACIA CORPORATION (US) 2007-08-21 US disclosed
CN-1768050-A Benzopyran compounds for the treatment of inflammation PHARMACIA CORP (US) 2006-05-03 CN disclosed
EP-1631562-A1 CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS Pharmacia Corporation (US) 2006-03-08 EP disclosed
EP-1615905-A2 BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS Pharmacia Corporation (US) 2006-01-18 EP disclosed
US-20050148627-A1 Benzopyran compounds for use in the treatment and prevention of inflammation related conditions CARTER JEFFERY (US) 2005-07-07 US disclosed
US-20050148777-A1 Benzopyran compounds useful for treating inflammatory conditions CARTER JEFFERY (US) 2005-07-07 US disclosed
WO-2004087687-A1 CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS PHARMACIA CORPORATION (US) 2004-10-14 WO disclosed
WO-2004087686-A2 BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS PHARMACIA CORPORATION (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197500-A1 NO-RELEASING GUANIDINE-CHROMENE CONJUGATES ARG1, ARGLU1, CGAS PTGS2 1336/4885PTGS1 901/4885
US-20050148777-A1 Benzopyran compounds useful for treating inflammatory conditions PTGES2, PTGER2, PTGS2 PTGS2 3/4885PTGS1 6/4885
US-10266511-B2 No-releasing nitrooxy-chromene conjugates NOS1, NOS2, NOS3 PTGS2 608/4885PTGS1 209/4885
US-20160340330-A1 NO-RELEASING NITROOXY-CHROMENE CONJUGATES NOS1, NOS2, NOS3 PTGS2 608/4885PTGS1 209/4885
US-20050148627-A1 Benzopyran compounds for use in the treatment and prevention of inflammation related conditions PTGES2, PTGER2, PTGES PTGS2 4/4885PTGS1 7/4885
US-20170196835-A1 COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT CD274, ICOS, PDCD1 PTGS2 3149/4885PTGS1 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.